Exit Options for John Hancock Bond and Corporate Finance Group: Hanover Communications In... - 28 Strategic Investors
- or -
Your request has been sent. Someone from the Aurigin team will be in touch with you shortly.
Please connect with us to get access to Impact Vault
United States of America
US$ 53M
Equity
Less than 50%
Growth Capital
US$ 43M
US$ 17M
Advisor
Yes
This entity is a US based Healthcare Technology developed with Revenue of USD 43 million and EBITDA of USD 17 million. The entity is global market-leading provider of FDA approved cost-effective proton therapy and imaging systems with enhanced accuracy and precision compared to competitive proton therapy systems. They are currently looking to raise USD 53 million to spend on Vendor acquisitions, production facilities, Global S&M Channels and Research.